NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Insperity, Inc. (“Insperity” or the “Company”) (NYSE: NSP). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Insperity and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On August 1, 202 ...

NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- As home care becomes a critical part of everyday health, the demand for gentle yet effective wound care has never been higher. Families and caregivers are seeking solutions that are safe, reliable, and user-friendly. In response to this growing need, Dimora Medical has introduced its latest product — the Dimora PHMB Skin and Wound Cleanser. Unlike alcohol, which can sting and harm new cells, PHMB targets germs while protecting skin. This makes the Dimora cleanser ...

In collaboration with River Partners, this transformative effort will help conserve water, restore habitat, and strengthen ecosystems and communities through long-term investment in climate resilience TAMPA, Fla. and STAMFORD, Conn., Aug. 25, 2025 /PRNewswire/ - As part of its ongoing commitment to responsible water stewardship, Primo Brands Corporation (NYSE: PRMB), a leading branded beverage company in North America with a focus on healthy hydration and owner of the Arrowhead® Mountain Spring Water Brand, ...

Group 1: Federal Reserve's Stance - Federal Reserve Chair Jerome Powell indicated a dovish tone, suggesting a potential rate cut due to a "curious balance" in the labor market with slowing hiring and a shrinking workforce [1][4] - Current market expectations are leaning towards lower rates, with nearly 87% of traders anticipating a 25-basis-point cut in September [2] Group 2: Market Reactions - Stocks experienced a rally following Powell's remarks, with the KBW Nasdaq Bank Index increasing by 3.2% and major banks like Citigroup, Bank of America, JPMorgan Chase, and Wells Fargo showing significant gains [3][10] Group 3: Labor Market and Economic Growth - Powell highlighted rising risks in the labor market, noting that while unemployment is low, hiring and labor supply are declining, which could lead to layoffs and increased joblessness [4] - The Fed is shifting its focus from controlling inflation to protecting jobs and sustaining economic momentum, indicating a more dovish approach [5] Group 4: Financial Conditions and Credit Flows - Elevated borrowing costs are impacting households and businesses, and a rate cut is aimed at easing financing pressures to sustain economic growth [6] - The Fed's rate reductions have begun to stabilize funding costs for banks, supporting net interest income expansion, which is crucial for profitability [7] Group 5: Impact on Banks - Lower rates are expected to relieve financial stress for borrowers, making refinancing more affordable and improving credit quality for banks [8] - Increased lending activity due to lower rates could enhance bank profitability, although the full impact may take time to materialize [9]

Core Insights - Precigen, Inc. (PGEN) shares surged 144.4% in August following FDA approval of Papzimeos for recurrent respiratory papillomatosis (RRP), marking a significant milestone as the first FDA-approved treatment for adults with this condition [1][6][4] - The drug, developed using Precigen's AdenoVerse platform, is a non-replicating adenoviral vector immunotherapy administered through four subcutaneous injections over 12 weeks, and has received breakthrough therapy and orphan drug designations from the FDA [2][4] - Year-to-date, PGEN's stock has increased by 273.2%, significantly outperforming the industry growth of 4.3% [5] FDA Approval Details - The FDA granted full approval for Papzimeos based on a pivotal phase I/II study, which demonstrated that 51% of patients achieved a complete response, eliminating the need for surgeries for 12 months post-treatment [4][6] - The approval means no confirmatory study is required, which has positively influenced investor sentiment [7] Market Strategy - Precigen plans to launch Papzimeos commercially, emphasizing the establishment of the therapy as the standard of care for adults with RRP [9] - The company has introduced Papzimeos SUPPORT, a patient services platform aimed at facilitating insurance processes and ensuring access to treatment, which is expected to enhance adoption and revenue growth [9] Competitive Landscape - Inovio (INO) is also developing a treatment for RRP, with plans to submit a rolling biologics license application for INO-3107 by the end of the year, supported by positive phase I/II study data [10][12] - Similar to Papzimeos, INO-3107 has received breakthrough therapy and orphan drug designations from the FDA [12]

Core Insights - Costco Wholesale Corporation (COST) reported strong third-quarter fiscal 2025 results, with net sales increasing 8% year over year to $62 billion, driven by digital commerce growth [1][9] - E-commerce sales saw a notable 14.8% increase in Q3, with adjusted growth reaching 15.7%, highlighting the company's ability to integrate digital and physical retail [9] Digital Commerce Performance - Digital momentum was evident with website traffic rising 20%, average order value increasing 3%, and Costco Logistics enhancing deliveries of bulky items by 31% [2][9] - Categories such as gold and jewelry, toys, health and beauty, and home furnishings experienced double-digit online gains, indicating a shift in consumer behavior towards higher-value digital purchases [2] Growth Initiatives - Costco's partnership with Affirm introduced Buy Now, Pay Later financing, making large-ticket items more accessible [3] - The implementation of personalized product recommendation tools and the expansion of the Costco Next marketplace improved the member experience while maintaining a value-first philosophy [3] Physical Store Performance - Comparable sales across the company rose 5.7%, with U.S. traffic up 5.5%, demonstrating strong performance in physical stores [4] - Membership renewal rates remained high at 92.7% in the U.S. and Canada, indicating sustained customer loyalty despite the growth in digital adoption [4] Overall Business Strategy - Costco's online business is evolving into a significant growth pillar, reinforcing its leadership in both physical retail and digital commerce [5] - The balance between warehouse operations and e-commerce is a key competitive advantage for Costco [4] Comparative Analysis - Costco's e-commerce growth is notable when compared to competitors, with Walmart Inc. reporting a 25% increase in global e-commerce sales and Sprouts Farmers Market achieving 27% growth [6][7] Stock Performance and Valuation - COST stock has outperformed the industry, with a 7.4% increase over the past year compared to the industry's 3.3% growth [8] - The forward 12-month price-to-earnings ratio for Costco stands at 48.19, higher than the industry average of 32.34, indicating a premium valuation [11]

Core Viewpoint - A class action lawsuit has been filed against Sarepta Therapeutics, Inc. for allegedly misleading investors regarding the safety and revenue outlook of its gene therapy ELEVIDYS, which is intended to treat Duchenne muscular dystrophy [1][3]. Company Overview - Sarepta Therapeutics is a biopharmaceutical company focused on developing gene therapies, specifically ELEVIDYS, for treating Duchenne muscular dystrophy [3]. Allegations and Misleading Statements - The lawsuit claims that Sarepta made materially false and misleading statements about ELEVIDYS, leading investors to believe it was a safe therapy with no hindrances to broader application approval [3]. - Specific allegations include: - ELEVIDYS posed significant safety risks to patients [3]. - Trial protocols failed to detect severe side effects [3]. - Adverse events would lead to halted recruitment and dosing in trials, attracting regulatory scrutiny [3]. - Positive statements made by the company lacked a reasonable basis due to undisclosed material adverse facts [3]. Stock Price Impact - Following a safety update on March 18, 2025, where a patient died after treatment with ELEVIDYS, Sarepta's stock price fell by $27.81 per share, or 27.44%, closing at $73.54 [4]. - On April 4, 2025, after the company disclosed regulatory scrutiny and halted recruitment, the stock price fell by $4.18 per share, or 7.13%, closing at $54.43 [4]. - A second patient death was reported on June 15, 2025, leading to a significant drop of $15.24 per share, or 42.12%, closing at $20.91 [4]. - Following an FDA Safety Communication on June 24, 2025, the stock price fell by $1.52 per share, or 8.01%, closing at $17.46 [4].

Group 1 - Fanatics Betting and Gaming is partnering with Boyd Gaming Corporation to launch online and retail sports betting in Missouri, with plans to debut in December 2025 [1][2]. - The agreement allows Fanatics Sportsbook to operate mobile sports betting under Boyd's license and to open retail sportsbooks at two Ameristar Casino locations [2][5]. - Fanatics Sportsbook will offer various betting markets for major sports, including professional and college football, basketball, hockey, and more, with all market development handled in-house [5][7]. Group 2 - Fanatics Betting and Gaming, launched in 2021, is the fastest growing sportsbook in America, reaching 95% of the addressable online sports bettor market in the U.S. [7]. - The company operates 22 retail sports betting locations, including the only sportsbook inside an NFL stadium [7]. - Boyd Gaming Corporation, celebrating its 50th anniversary in 2025, operates 28 gaming properties across 10 states and manages a tribal casino [8].

U.S. stocks were mixed, with the Dow Jones index falling more than 200 points on Monday.Shares of Keurig Dr Pepper Inc. KDP fell sharply during Monday's session after the company announced the acquisition of JDE Peet’s.Keurig Dr Pepper shares dipped 7.8% to $32.38 on Monday.Here are some other big stocks recording losses in today’s session.Valneva SE VALN shares fell 21% to $9.19 after the FDA suspended the license for IXCHIQ.DeFi Development Corp. DFDV dipped 18% to $16.51 after the company announced that ...

Core Insights - Deckers Outdoor Corporation's international business is a key growth driver, with HOKA and UGG showing strong performance abroad, particularly in the first quarter of fiscal 2026 where international revenues increased by 49.7% year over year to $463.3 million, significantly outperforming U.S. sales [1][10] International Business Performance - HOKA's international growth is robust, especially in the EMEA region, with record European reorders and strong consumer acquisition. Key products like Bondi, Clifton, and Arahi are leading sales, with Bondi and Clifton being top U.S. running franchises and doubling volumes in China for spring/summer 2025 [2] - UGG has also seen strong international growth, particularly in Europe and China. The brand's 365 strategy has expanded its appeal beyond cold-weather items, with new styles like the PeakMod clog gaining popularity, supported by effective marketing campaigns [3] Infrastructure and Strategic Investments - To meet rising demand, Deckers has invested in infrastructure, including changing its EMEA logistics provider and opening new stores in cities like Berlin, Milan, and various locations in China. These initiatives aim to enhance retail presence and build long-term brand equity [4] Future Outlook - Management anticipates that international markets will continue to outpace U.S. growth, with HOKA positioned as the fastest-growing brand and UGG expanding its seasonal and demographic reach. The goal is to increase international sales to 50% of total revenues, creating a more balanced and resilient business model [5] Competitive Landscape - In comparison, Steven Madden, Ltd. reported an 8% year-over-year increase in international revenues for the second quarter of 2025, while Wolverine World Wide, Inc. saw a 15.7% increase to $250 million, both outpacing U.S. sales [6][7][8] Valuation and Earnings Estimates - Deckers shares have declined by 46.3% year to date, contrasting with the industry's decline of 9.6%. The company trades at a forward price-to-earnings ratio of 16.80X, below the industry average of 18.22X [9][12] - The Zacks Consensus Estimate for Deckers' fiscal 2026 earnings suggests a slight decline of 0.6%, while fiscal 2027 indicates an 8.3% increase, with recent upward revisions in earnings estimates for both fiscal years [13]